Relmada Therapeutics
RLMD | NASDAQ
$3.61
-$0.60 (-14.25%)
At close: Nov 16, 2026, 4:00 PM ET
$3.61
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-14.25%
(1D)No price chart data available for 1D timeframe.
Rating
37.2
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #607/1021 (Top 59%)
Key Statistics
Market Data
Market Cap $405.9M
1D Range
3.46 4.13
52W Range
3.10 7.86
Valuation (TTM)
PE -4.88
PB 2.10
EV/EBITDA -3.14
Valuation (NTM)
Forward PE N/A
Forward PEG 0.12
Price Target $12.00
Cash Flow
FCF Yield -12.8%
SBC Adj. FCF Yield -14.3%
SBC Impact -11.8%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 59.1% |
40.5%
FCF 3Y | 5Y 1.4% |
22.1%
Returns
ROA -32.0%
ROE -37.3%
ROIC -34.4%
Financial Health
Net Cash
$202.12M
Current Ratio 26.37
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of g...
Sector Healthcare
Industry Biotechnology
Employees 17
IPO Date Jun 20, 2014
Website www.relmada.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$12.00
Upside
+232.41%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove RLMD